Literature DB >> 28516380

Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment.

Kiyotaka Nakamagoe1, Tetuya Moriyama2, Hiroshi Maruyama3, Masahiro Yokosawa4, Tadashi Hara5, Shinya Tanaka2, Manabu Fujimoto3, Akira Tamaoka2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28516380     DOI： 10.1007/s00432-017-2410-x

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  6 in total

1.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-09-24       Impact factor: 91.245

2.  A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use.

Authors:  Aasems Jacob; Dileep C Unnikrishnan; Aju Mathew; Braghadheeswar Thyagarajan; Shil Patel
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-17       Impact factor: 4.553

3.  In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.

Authors:  Changyu Wang; Kent B Thudium; Minhua Han; Xi-Tao Wang; Haichun Huang; Diane Feingersh; Candy Garcia; Yi Wu; Michelle Kuhne; Mohan Srinivasan; Sujata Singh; Susan Wong; Neysa Garner; Heidi Leblanc; R Todd Bunch; Diann Blanset; Mark J Selby; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2014-05-28       Impact factor: 11.151

4.  An evaluation of criteria for polymyalgia rheumatica.

Authors:  H A Bird; W Esselinckx; A S Dixon; A G Mowat; P H Wood
Journal:  Ann Rheum Dis       Date:  1979-10       Impact factor: 19.103

5.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Authors:  Bhaskar Dasgupta; Marco A Cimmino; Hilal Maradit-Kremers; Wolfgang A Schmidt; Michael Schirmer; Carlo Salvarani; Artur Bachta; Christian Dejaco; Christina Duftner; Hanne Slott Jensen; Pierre Duhaut; Gyula Poór; Novák Pál Kaposi; Peter Mandl; Peter V Balint; Zsuzsa Schmidt; Annamaria Iagnocco; Carlotta Nannini; Fabrizio Cantini; Pierluigi Macchioni; Nicolò Pipitone; Montserrat Del Amo; Georgina Espígol-Frigolé; Maria C Cid; Víctor M Martínez-Taboada; Elisabeth Nordborg; Haner Direskeneli; Sibel Zehra Aydin; Khalid Ahmed; Brian Hazleman; Barbara Silverman; Colin Pease; Richard J Wakefield; Raashid Luqmani; Andy Abril; Clement J Michet; Ralph Marcus; Neil J Gonter; Mehrdad Maz; Rickey E Carter; Cynthia S Crowson; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103

6.  Myasthenic crisis and polymyositis induced by one dose of nivolumab.

Authors:  Toshihiro Kimura; Satoshi Fukushima; Azusa Miyashita; Jun Aoi; Masatoshi Jinnin; Takayuki Kosaka; Yukio Ando; Masakazu Matsukawa; Hiroyuki Inoue; Kazuma Kiyotani; Jae-Hyun Park; Yusuke Nakamura; Hironobu Ihn
Journal:  Cancer Sci       Date:  2016-07       Impact factor: 6.716
  6 in total
  6 in total

1.  Polymyalgia rheumatica in a melanoma patient 11 months after completion of immunotherapy with nivolumab.

Authors:  Yolanka Lobo; Phillip Good; Felicity Murphy
Journal:  Cancer Rep (Hoboken)       Date:  2020-04-06

Review 2.  Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.

Authors:  Devis Benfaremo; Lucia Manfredi; Michele Maria Luchetti; Armando Gabrielli
Journal:  Curr Drug Saf       Date:  2018

3.  Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Authors:  Noha Abdel-Wahab; Maria E Suarez-Almazor
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

4.  Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.

Authors:  Jan Leipe; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

5.  Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database.

Authors:  Koki Kato; Tomohiro Mizuno; Takenao Koseki; Yoshimasa Ito; Kazuo Takahashi; Naotake Tsuboi; Shigeki Yamada
Journal:  Front Pharmacol       Date:  2022-03-25       Impact factor: 5.810

Review 6.  Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.

Authors:  Yan Xiao; Lin Zeng; Qinglin Shen; Zhiyong Zhou; Zhifang Mao; Qin Wang; Xiquan Zhang; Yingliang Li; Weirong Yao
Journal:  J Immunol Res       Date:  2020-08-04       Impact factor: 4.818
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.